natgillin/translations-raw huggingface dataset:
Gently shake the multidose vial each time before withdrawing a dose (0.5 ml) of the vaccine into a syringe. 
Pred vsakim odvzemom odmerka (0,5 ml) cepiva v brizgo previdno pretresite večodmerno vialo.
Two doses of vaccine containing H9N2 (A/chicken/Hong Kong/G9/97) strain at 4 different dosages (3.75, 7.5, 15 and 30 µg HA/dose), were administered four weeks apart. 
V presledku 4 tednov so pri 4 različnih odmerkih (3,75; 7,5; 15 in 30 μg HA/odmerek) uporabili dva odmerka cepiva, ki je vsebovalo sev H9N2 (A/Chicken/Hong Kong/G9/97).
0.66 milligrams 
0,66 miligramov citronska kislina
MN results for the clinical studies in the Table above revealed a seroprotection rate against A/turkey/Turkey/05 ranging from 27% (17-39) (V87P1) to 39% (32-46) (V87P13) and seroconversion rate of 36% (29-43) for study V87P13. 
A/turkey/Turkey/05 v razponu od 27 % (17-39) (V87P1) do 39 % (32-46) (V87P13) in stopnjo serokonverzije 36 % (29-43) za študijo V87P13.
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in subjects aged over 60 (limited number of subjects were above 70 years of age) measured by SRH assay assessed in two clinical studies were as follows: 
H5N1 A/Vietnam/1194/2004 pri preiskovancih, starejših od 60 let (omejeno število preiskovancev je bilo starejših od 70 let), izmerjeni s testom SRH in ocenjeni v dveh kliničnih študijah, so bili, kot sledi:
A clinical trial (Study V87P6) was conducted with a H5N1 vaccine combined with MF59C.1 adjuvant (n=334) vs seasonal influenza vaccine (n=137). 
MF59C.1 (n = 334), s sezonskim cepivom proti gripi (n = 137).
7.5 micrograms haemagglutinin 
7,5 mikrogramov hemaglutinina
Seroprotection rate (95%CI)° Seroconversion rate (95%CI)° 
Stopnja serozaščite (95-odstotni IZ)° Delež serokonverzije (95-odstotni IZ)°
A Phase II clinical trial (Study V87P1) was conducted with a H5N1 vaccine combined with MF59C.1 adjuvant in 312 healthy adults. 
Pri 312 zdravih odraslih prostovoljcih so izvedli klinično preskušanje 2. faze (študija V87P1) s kombinacijo cepiva H5N1 in adjuvansa MF59C.1.
CHMP immunogenicity criteria set for adults (18-60 years) were met both after the 1st and the 2nd dose in all the above age strata (both in the overall population and in the subset seronegative at baseline). 
V vseh navedenih starostnih skupinah (v celotni populaciji in v podskupini v izhodišču seronegativnih oseb) so bili po prvem in drugem odmerku doseženi kriteriji CHMP za imunogenost za odrasle (18-60 let).
MN results for the clinical studies in the Table above revealed a seroprotection rate against A/turkey/Turkey/05 ranging from 11% (3-25) (study V87P1) to 30% (24-37) (study V87P13) and seroconversion rate of 25% (19-31) for study V87P13. 
A/turkey/Turkey/05 v razponu od 11 % (3-25) (študija V87P1) do 30 % (24-37) (študija V87P13) in stopnjo serokonverzije 25 % (19-31) za študijo V87P13.
Package leaflet: Information for the user Foclivia suspension for injection in multidose container 
Foclivia suspenzija za injiciranje v vsebniku z več odmerki.
ANNEX II A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT E. SPECIFIC OBLIGATIONS TO COMPLETE POST AUTHORISATION MEASURES FOR THE MARKETING AUTHORISATION UNDER EXCEPTIONAL CIRCUMSTANCES 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
It is provided in a vial containing a single dose (0.5 ml) for injection. 
Na voljo je v vialah, ki vsebujejo enkratni odmerek (0,5 ml) za injiciranje.
Adverse reactions in the week following vaccination with Focetria H1N1v from 73 infants 6-11 months old and 73 toddlers 12-35 months old, receiving the 7.5 µg formulation were reported as follows: 
11 mesecev, in 73 malčkih, starih 12-35 mesecev, ki so prejeli formulacijo 7,5 µg, so bili, kot sledi:
Persistence of antibodies after primary vaccination in this population as assessed by HI, SRH, and MN tests reduced from 1/2 to 1/5th of their post-vaccination level at day 202 as compared to day 43 after completion of primary schedules as assessed by HI, SRH, and MN tests. 
V primerjavi z ravnmi protiteles, pridobljenimi 43. dan po zaključku primarnega režima cepljenja, so bile ravni protiteles 202. dan zmanjšane od 1/5 do 1/2 glede na predhodne ravni, izmerjene s testi HI, SRH in MN. Do 50 % starejših oseb, imuniziranih s cepivom proti H5N1 z dodanim MF59C, je bilo v šestem mesecu serozaščitenih.
Serious unlisted adverse reactions (SOC, HLT, PTs) stratified according to type of report (medically confirmed or non-medically confirmed), for the period covered by the report and cumulatively. 
Hudi nenavedeni neželeni učinki (OS, HLT, PI), stratificirani glede na vrsto poročila (medicinsko potrjena ali nemedicinsko potrjena) in glede na obdobje, ki ga poročilo pokriva, ter kumulativno.
Common (may affect up to 1 in 10 people). 
Pogosti (se lahko pojavijo pri največ 1 cepljeni osebi od 10 cepljenih oseb).
All spontaneous adverse reactions (SOC, HLT, PT) occurring in pregnant women, stratified according to type of report (medically confirmed or non-medically confirmed), for the period covered by the report and cumulatively. 
Vsi spontani neželeni učinki (OS, HLT, PI) pri nosečnicah, stratificirani glede na vrsto poročila (medicinsko potrjena ali nemedicinsko potrjena) in glede na obdobje, ki ga poročilo pokriva, ter kumulativno.
All spontaneous adverse reactions by age group, per SOC, HLT and PT, stratified according to type of report (medically confirmed or non-medically confirmed), for the period covered by the report and cumulatively. 
Vsi spontani neželeni učinki glede na starostno skupino po OS, HLT in PI, stratificirani glede na vrsto poročila (medicinsko potrjena ali nemedicinsko potrjena) in glede na obdobje, ki ga poročilo pokriva, ter kumulativno.
You should discuss with your doctor whether you should receive Foclivia. 
O cepljenju z zdravilom FOCLIVIA se posvetujte z zdravnikom.
Uncommon: (may affect up to 1 in 100 people). 
Občasni (se lahko pojavijo pri največ 1 cepljeni osebi od 100 cepljenih oseb).
It is provided in a vial containing ten doses (0.5 ml each) for injection. 
Viala vsebuje 10 odmerkov (0,5 ml na odmerek) za injiciranje.
Pandemic Influenza Vaccine (surface antigen, inactivated, adjuvanted) I.M. 
cepivo proti pandemični gripi (površinski antigeni, inaktivirani, z adjuvansom)
Baseline Serostatus 
Serostatus ob izhodišču
Seroprotection rate (95%CI)* Seroconversion rate (95%CI)* Seroconversion factor (95%CI)** 
Delež serokonverzije (95-odstotni IZ)* Faktor serokonverzije (95-odstotni IZ)**
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL FOR 10-DOSE VIAL 
OVOJNINAH OZNAKA ZA VIALO Z DESETIMI ODMERKI
Therefore, tell the doctor or nurse if you fainted with a previous injection. 
če ste omedleli pri kakšnem prejšnjem injiciranju.
Study V87P1 21 days after 2nd dose N=84 
Študija V87P1 21. dan po 2. odmerku n = 84
Study V87P13 21 days after 2nd dose N=66 
Študija V87P13 21. dan po 2. odmerku n = 66
Caution is needed when administrating this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance, to any of the excipients listed in section 6.1 and to eggs, chicken proteins, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB). 
Pri uporabi tega cepiva pri osebah z znano preobčutljivostjo (razen anafilaktičnih reakcij) na učinkovino, katero koli pomožno snov, navedeno v poglavju 6.1, in na jajca, piščančje beljakovine,
Particular attention should be given to subjects suffering from epilepsy and the physician should inform the subjects (or parents) about the possibility to experience convulsion. 
Zdravnik mora te osebe (ali starše) obvestiti o možnosti konvulzij (glejte poglavje 4.8).
Study V87P1 21 days after 2nd dose N=70 
Študija V87P1 21. dan po 2. odmerku n = 70
Milky-white liquid. 
Guillain-Barréjev sindrom.
Study V87P13 21 days after 2nd dose N=128 
Študija V87P13 21. dan po 2. odmerku n = 128
OTHER 
OKOLIŠČINAH
Study V87P13 21 days after 2nd dose N=69 
Študija V87P13 21. dan po 2. odmerku n = 69
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL FOR SYRINGE AND 1-DOSE VIAL 
OVOJNINAH OZNAKA ZA BRIZGO IN VIALO Z ENIM ODMERKOM
Foclivia suspension for injection Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) 
Foclivia suspenzija za injiciranje cepivo proti pandemični gripi (H5N1) (površinski antigen, inaktiviran, z adjuvansom)
Study V87P1 21 days after 2nd dose N=37 
Študija V87P1 21. dan po 2. odmerku n = 37
Study V87P13 21 days after 2nd dose N=197 
Študija V87P13 21. dan po 2. odmerku n = 197
Study V87P13 21 days after 2nd dose N=210 
Študija V87P13 21. dan po 2. odmerku n = 210
Study V87P1 21 days after 2nd dose N=149 
Študija V87P1 21. dan po 2. odmerku n = 149
Foclivia suspension for injection Pandemic Influenza Vaccine (surface antigen, inactivated, adjuvanted) 
Foclivia suspenzija za injiciranje cepivo proti pandemični gripi (površinski antigeni, inaktivirani, z adjuvansom)
Study V87P13 21 days after 2nd dose N=207 
Študija V87P13 21. dan po 2. odmerku n = 207
General disorders and administration site conditions Asthenia. 
Splošne težave in spremembe na mestu aplikacije astenija
Study V87P13 21 days after 2nd dose N=143 
Študija V87P13 21. dan po 2. odmerku n = 143
Foclivia suspension for injection in pre-filled syringe Pandemic Influenza Vaccine (surface antigen, inactivated, adjuvanted) 
Foclivia suspenzija za injiciranje v napolnjeni injekcijski brizgi cepivo proti pandemični gripi (površinski antigeni, inaktivirani, z adjuvansom)
A clinical trial (study V87P6) was conducted with a H5N1 vaccine combined with MF59C.1 adjuvant in 471 children from 6 months to 17 years of age. 
Neželeni učinki iz kliničnih preskušanj pri otrocih, starih od 6 mesecev do 17 let V kliničnem preskušanju (študija V87P6) so primerjali cepivo H5N1, kombinirano z adjuvansom
Foclivia suspension for injection in multidose container Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) 
Foclivia suspenzija za injiciranje v vsebniku z več odmerki cepivo proti pandemični gripi (H5N1) (površinski antigen, inaktiviran, z adjuvansom)
Foclivia suspension for injection in pre-filled syringe Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) 
Foclivia suspenzija za injiciranje v napolnjeni injekcijski brizgi cepivo proti pandemični gripi (H5N1) (površinski antigen, inaktiviran, z adjuvansom)
Single dose vial: 1 vial containing a single dose (0.5 ml) for injection Instructions for administration of the vaccine: 
Viala z enkratnim odmerkom: 1 viala, ki vsebuje enkratni odmerek (0,5 ml) za injiciranje.
Gastrointestinal disorders Gastrointestinal disorders such as nausea, vomiting, abdominal pain and diarrhoea. 
angioedem Bolezni prebavil prebavne bolezni, vključno z navzeo, bruhanjem, trebušne bolečine in driska Bolezni živčevja glavobol, omotica, somnolenca, sinkopa.
Foclivia contains Thiomersal as a preservative and it is possible that you may experience an allergic reaction. 
Zdravilo Foclivia vsebuje tiomersal kot konzervans.
The other ingredients are: thiomersal, sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate and water for injections. 
Pomožne snovi so tiomersal, natrijev klorid, kalijev klorid, kalijev dihidrogen fosfat, natrijev hidrogenfosfat dihidrat, magnezijev klorid heksahidrat, kalcijev klorid dihidrat in voda za injekcije.
Sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate, thiomersal, water for injections. 
Natrijev klorid, kalijev klorid, kalijev dihidrogenfosfat, natrijev hidrogenfosfat dihidrat, magnezijev klorid heksahidrat, kalcijev klorid dihidrat, tiomersal, voda za injekcije.
Sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate, water for injections. 
Natrijev klorid, kalijev klorid, kalijev dihidrogenfosfat, natrijev hidrogenfosfat dihidrat, magnezijev klorid heksahidrat, kalcijev klorid dihidrat, voda za injekcije.
Name and address of the manufacturer responsible for batch release Seqirus Vaccines Ltd 
Ime in naslov izdelovalca, odgovornega za sproščanje serije
Foclivia injection 
suspenzija za injiciranje Viala
The other ingredients are: sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate and water for injections. 
Pomožne snovi so natrijev klorid, kalijev klorid, kalijev dihidrogen fosfat, natrijev hidrogenfosfat dihidrat, magnezijev klorid heksahidrat, kalcijev klorid dihidrat in voda za injekcije.
You should discuss with your doctor whether you should receive FOCLIVIA The vaccine may be used during lactation. 
O cepljenju z zdravilom Foclivia se posvetujte z zdravnikom.
AESIs will be defined as follows: 
single radial haemolysis), so bili, kot sledi:
List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States 
SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI, ZDRAVILA, POTI UPORABE, IMETNIKOV DOVOLJENJ ZA PROMET V DRŽAVAH ČLANICAH
2719 EE Zoetermeer The Netherlands 
2719 EE Zoetermeer Nizozemska
AstraZeneca Kft. 1113 Budapest, Bocskai út 134-146 Hungary 
Madžarska AstraZeneca Kft. 1113 Budapest, Bocskai út 134-146 Madžarska
Netherlands AstraZeneca BV Louis Pasteurlaan 5 
Nizozemska AstraZeneca BV Louis Pasteurlaan 5
DK-2620 Albertslund, Denmark 
DK-2620 Albertslund, Danska
AstraZeneca AS Boks 200 Vinderen NO-0319 Oslo, Norway 
Norveška AstraZeneca AS Boks 200 Vinderen NO-0319 Oslo,
AstraZeneca SA Theotokopoulou 4 & Astronafton 151 25 Maroussi Greece 
Theotokopoulou 4 & Astronafton 151 25 Maroussi Grčija
Almirall S.A., Ronda General Mitre, 151 08022 Barcelona, Spain 
Ronda General Mitre, 151 08022 Barcelona, Španija
AstraZeneca GmbH 22876 Wedel, Germany 
AstraZeneca GmbH 22876 Wedel, Nemčija
AstraZeneca SpA Palazzo Volta-via F Sforza - 20080 Basiglio (MI)Italy 
Palazzo Volta-via F Sforza - 20080 Basiglio (MI) - Italija
AstraZeneca 1, Place Renault 92844 RueilMalmaison Cedex France 
1, Place Renault 92844 Rueil-Malmaison Cedex Francija
AstraZeneca A/S Roskildevej 22, DK2620 Albertslund, Denmark 
AstraZeneca A/S Roskildevej 22, DK-2620 Albertslund, Danska
Czech Republic AstraZeneca UK Ltd., Macclesfield, Cheshire, United Kingdom 
AstraZeneca UK Ltd., Macclesfield, Cheshire,
WC2B 4AE, United Kingdom 
London,WC2B 4AE, Velika Britanija
Capability Green, Luton, LU1 3LU, United Kingdom 
AstraZeneca UK Limited, 600 Capability Green, Luton, LU1 3LU, Velika Britanija
Viktoriaallee 3-5, 52066 Aachen, Germany 
Takeda Pharma GmbH, Viktoriaallee 3-5, 52066 Aachen, Nemčija
Laboratoires Takeda, 11-15, quai de Dion Bouton, 
Laboratoires Takeda, 11-15, quai de Dion Bouton, 92816 Puteaux Cedex, Francija
AstraZeneca UK Limited 
Slovenija AstraZeneca UK Limited 15 Stanhope Gate
LusomedicamentaSociedade Técnica Farmacêutica, S.A., Estrada Consiglieri Pedroso, 69 BQueluz de Baixo 2730-055 Barcarena, Portugal 
Portugalska Lusomedicamenta - Sociedade Técnica Farmacêutica, S.A., Estrada Consiglieri Pedroso, 69 BQueluz de Baixo
28033 Madrid, Spain 
2730-097 Barcarena, Portugalska
AstraZeneca AB 151 85 Södertälje, Sweden 
AstraZeneca AB 151 85 Södertälje, Švedska
B-1180 Brussels 
NV AstraZeneca SA Egide Van Ophemstraat 110 B-1180 Brussels Belgija
AstraZeneca AB, S151 85 Södertälje, Sweden 
AstraZeneca AB, S-151 85 Södertälje, Švedska
AstraZeneca AB, Strängnäsvägen 44, S-151 85 Södertälje, Sweden 
AstraZeneca AB, S-151 85 Södertälje, švedska
Hytacand 16 mg 16 mg / 12.5 mg 
Atacand Plus 16 mg/12.5 mg 16 mg / 12.5 mg
The European Commission granted a marketing authorisation valid throughout the European Union for Hexyon on 17 April 2013. 
Evropska komisija je dovoljenje za promet z zdravilom Hexyon, veljavno po vsej Evropski uniji, izdala 17. aprila 2013.
What measures are being taken to ensure the safe and effective use of Hexyon? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Hexyon?
Other information about Hexyon 
Druge informacije o zdravilu Hexyon
The full EPAR for Hexyon can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Hexyon je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Vaccination with Hexyon should be carried out according to official recommendations. 
Cepljenje s cepivom Hexyon je treba izvajati v skladu z uradnimi priporočili.
This is a summary of the European public assessment report (EPAR) for Hexyon. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Hexyon.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Hexyon's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Hexyon večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Hexyon is a vaccine. 
Zdravilo Hexyon je cepivo.
The effects were compared with a combination of separate vaccines designed to protect against the diseases included in Hexyon. 
Učinke so primerjali s kombinacijo ločenih cepiv, namenjenih za zaščito pred boleznimi, ki so vključene v cepivo Hexyon.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Hexyon have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo zdravstveni delavci in bolniki upoštevati za varno in učinkovito uporabo cepiva, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Hexyon contains small amounts of materials derived from the bacteria and viruses it protects against. 
Zdravilo Hexyon vsebuje majhne količine materiala, pridobljenega iz bakterij in virusov, proti katerim ščiti.
Regarding safety, the CHMP considered that Hexyon's overall safety profile is similar to other vaccines, although vaccination with Hexyon is more likely than similar vaccines to cause reactions (mainly at the injection site). 
Kar zadeva varnost, je CHMP mnenja, da je celotni varnostni profil cepiva Hexyon podoben drugim cepivom, čeprav je bolj verjetno, da bo cepivo Hexyon povzročilo reakcije (večinoma na mestu injiciranja), kot druga cepiva.
It must not be used in children who have an uncontrolled or severe illness affecting the brain or nervous system, such as uncontrolled epilepsy, unless the condition has stabilised with treatment and the benefit clearly outweighs the risk. 
Ne sme se uporabljati pri otrocih, ki imajo nenadzorovana ali resna obolenja možganov ali živčnega sistema, kot je nenadzorovana epilepsija (napadi), razen če se je stanje z zdravljenjem ustalilo in so koristi cepljenja veliko večje od tveganj.
What are the risks associated with Hexyon? 
Kakšna tveganja so povezana z zdravilom Hexyon?
What benefits of Hexyon have been shown in studies? 
Kakšne koristi je zdravilo Hexyon izkazalo v študijah?
Why is Hexyon approved? 
Zakaj je bilo zdravilo Hexyon odobreno?
For more information about treatment with Hexyon, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Hexyon preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is Hexyon and what is it used for? 
Kaj je zdravilo Hexyon in za kaj se uporablja?
Hexyon has been studied in several countries worldwide in 12 main studies involving over 3,400 children between six weeks and two years of age who were given three doses of the vaccine during their first six months of life according to different local vaccination schedules. 
Cepivo Hexyon je bilo proučevano v različnih državah sveta v 12 glavnih študijah, ki so vključevale več kot 3 400 otrok, starih od šest tednov do dveh let, in ki so v skladu z različnimi lokalnimi shemami cepljenja prejeli tri odmerke cepiva v prvih šestih mesecih življenja.
It is not intended to provide practical advice on how to use Hexyon. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Hexyon must not be used in children who have ever had an allergic reaction to Hexyon or a vaccine containing the same components, including substances used during the manufacture of the vaccine and which may be found at extremely low levels (such as the antibiotics neomycin or streptomycin). 
Cepiva Hexyon se ne sme uporabljati pri otrocih, ki so v preteklosti imeli alergijsko reakcijo nanj ali cepivo, ki vsebuje enake sestavine, vključno s snovmi, ki se uporabljajo med procesom izdelave cepiva in ki so lahko prisotne v zelo majhnih količinah (kot sta antibiotika neomicin ali streptomicin).
The most common side effects with Hexyon include pain and redness at the site of injection, irritability and crying. 
Najpogostejši neželeni učinki cepiva Hexyon vključujejo bolečino in rdečico na mestu injiciranja, razdražljivost in jok.
For practical information about using Hexyon, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Hexyon naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Vaccination with Hexyon should be postponed if a child has a moderate to severe fever. 
Cepljenje s cepivom Hexyon je treba odložiti, če ima otrok srednje ali zelo povišano telesno temperaturo.
Hexyon or an appropriate combination of other vaccines can be used for the booster dose. 
Za poživitveni odmerek se lahko uporabi cepivo Hexyon ali ustrezna kombinacija drugih cepiv.
Hexyon is available as a suspension for injection in vials and prefilled syringes. 
Cepivo Hexyon je na voljo kot suspenzija za injiciranje v vialah in napolnjenih injekcijskih brizgah.
For the full list of all side effects reported with Hexyon, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Hexyon, glejte navodilo za uporabo.
The studies showed that protective antibody levels against the various diseases developed in between 90 and 100% of children after the first three doses of Hexyon; protection was maintained or improved when a booster dose was given. 
Študije so pokazale, da so se zaščitne ravni protiteles, ki ščitijo pred različnimi boleznimi, razvile pri 90 do 100 % otrok po prvih treh odmerkih cepiva Hexyon.
These studies showed that Hexyon produces similar antibody profiles over time to comparable vaccines, and that the vaccine can be given at the same time as Prevenar and Rotarix. 
Te študije so pokazale, da so po določenem času profili protiteles, ustvarjeni s cepivom Hexyon, podobni tistim, ki jih ustvarijo primerjalna cepiva, in da se sme cepivo uporabljati sočasno s cepivoma Prevenar in Roatrix.
Hexyon is given by deep injection into a muscle, normally in the upper thigh or the shoulder. 
Cepivo Hexyon se daje običajno z injekcijo globoko v stegensko ali ramensko mišico.
It must not be used in children who have ever had encephalopathy (a brain disease) of unknown cause within seven days of receiving a vaccine containing pertussis components in the past. 
Cepivo Hexyon se ne sme uporabljati pri otrocih, ki so v preteklosti preboleli encefalopatijo (obolenje možganov) neznanega vzroka v sedmih dneh po prejemu cepiva, ki je vsebovalo komponente oslovskega kašlja.
How does Hexyon work? 
Kako zdravilo Hexyon deluje?